
enCore Energy Announces Expansion of the Alta Mesa Uranium Project
William M. Sheriff, Executive Chairman of enCore Energy, stated: "On behalf of the Board, I extend our congratulations to our land department which worked for many months to assemble this strategic land acquisition that significantly expands the Alta Mesa Uranium Project. The compelling geology and location, immediately adjacent to, and on-trend with, our active and past wellfields make this a key acquisition for enCore. We will begin an aggressive exploration program, following up on mineralization discovered by Chevron in the late 1970's, which lies along projected trends extending from several of the wellfields at Alta Mesa."
Highlights for the Tacubaya acquisition include:
Over 5,900 acres of private land consisting of mineral and surface leases with private parties located immediately adjacent to, and east of, enCore's Alta Mesa Uranium Project;
Tacubaya is a part of the Alta Mesa Uranium Project joint venture ("JV") between enCore Energy (70%) and Boss Energy Ltd. (30%);
Tacubaya's uranium mineralization occurs as roll fronts in multiple stacked sands within the Goliad Formation just as it does at the Alta Mesa Uranium Project;
Historical drilling completed by Chevron Minerals during the late 1970's discovered multiple uranium roll fronts located at various depths within multiple sand units interpreted to be the lower C, middle C, B and A sands, all of which have been, or are currently productive, at the Alta Mesa Uranium Project;
Additional exploration will be required to fully explore and delineate uranium mineralization on Tacubaya;
Projected continuation of productive roll fronts from Alta Mesa Wellfields 1, 3, 4, 5B and the currently operating Wellfield 7; and
Initial exploration to include a 200-hole drilling program beginning in two key areas utilizing several rigs. Two rigs will begin in October 2025, with an additional two drill rigs being added as the program progresses.
To view the project map, please visit: https://shorturl.at/sBh69
About the Alta Mesa ISR Uranium CPP and Wellfield ("Alta Mesa Uranium Project")
The Alta Mesa Uranium Project hosts a fully licensed and operational ISR Central Processing Plant and operational wellfield located on 200,000+ acres of private land and mineral rights in and regulated by the state of Texas. Total operating capacity at the Alta Mesa CPP is 1.5 million pounds uranium per year with additional drying capacity of 0.5 million pounds. The Alta Mesa Uranium Project operates under a 70/30 joint venture with Boss Energy Limited which is managed by the Company.
The Alta Mesa Uranium Project utilizes well known ISR technology to extract uranium in a non-invasive process using natural groundwater and oxygen. Currently, oxygenated water is being circulated in the wellfield through injection or extraction wells plumbed directly into the primary pipelines feeding the Alta Mesa CPP. Expansion of the wellfield will continue, with extraction to steadily increase from the wellfield as expansion continues through 2025 and beyond. The Alta Mesa CPP historically produced nearly 5 million pounds of uranium between 2005 and 2013 when production was curtailed as a result of low prices.
John M. Seeley, Ph.D., P.G., C.P.G., enCore's Chief Geologist, and a Qualified Person under Canadian National Instrument 43-101 and S-K 1300, has reviewed and approved the technical disclosure in this news release on behalf of the Company.
About enCore Energy Corp.
enCore Energy Corp., America's Clean Energy Company™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of In-Situ Recovery ("ISR") uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. enCore operates the 100% owned and operated Rosita CPP in South Texas and the Alta Mesa CPP & Project under a 70/30 joint venture with Boss Energy Ltd.
Following upon enCore's demonstrated success in South Texas, future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.
Cautionary Note Regarding Forward Looking Statements:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws that are based on management's current expectations, assumptions, and beliefs. Forward-looking statements can often be identified by such words as "expects", "plans", "believes", "intends", "continue", "potential", "remains", and similar expressions or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may", "could", or "will" be taken.
Forward-looking statements and information that are not statements of historical fact include, but are not limited to, any information relating to statements regarding future or potential extraction, and any other statements regarding future expectations, beliefs, goals or prospects, statements regarding the success of current and future ISR operations, including projects in our pipeline, our development plans, the anticipated timeline for starting exploration drilling related to Tacubaya, anticipated synergies of Tacubaya with the Alta Mesa Uranium Project, our future extraction plans and expectations and our commitment to working with local communities and indigenous governments to create positive impact from corporate developments should be considered forward looking statements. All such forward-looking statements are not guarantees of future results and forward-looking statements are subject to important risks and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results to differ materially from those expressed in any forward looking statement, including those described in greater detail in our filings with the SEC and on SEDAR+, particularly those described in our Annual Report on Form 10-K, annual information from and MD&A. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with assumptions regarding project economics; discount rates; expenditures and the current cost environment; timing and schedule of the projects, general economic conditions; adverse industry events; future legislative and regulatory developments; the ability of enCore to implement its business strategies; and other risks. A number of important factors could cause actual results or events to differ materially from those indicated or implied by such forward-looking statements, including without limitation exploration and development risks, changes in commodity prices, access to skilled personnel, the results of exploration and development activities; extraction risks; uninsured risks; regulatory risks; defects in title; the availability of materials and equipment, timeliness of government approvals and unanticipated environmental impacts on operations; litigation risks; risks posed by the economic and political environments in which the Company operates and intends to operate; increased competition; assumptions regarding market trends and the expected demand and desires for the Company's products and proposed products; reliance on industry equipment manufacturers, suppliers and others; the failure to adequately protect intellectual property; the failure to adequately manage future growth; adverse market conditions, the failure to satisfy ongoing regulatory requirements and factors relating to forward looking statements listed above. Should one or more of these risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. The Company assumes no obligation to update the information in this communication, except as required by law. Additional information identifying risks and uncertainties is contained in filings by the Company with the various securities commissions which are available online at www.sec.gov and www.sedarplus.ca. Forward-looking statements are provided for the purpose of providing information about the current expectations, beliefs and plans of management. Such statements may not be appropriate for other purposes and readers should not place undue reliance on these forward-looking statements, that speak only as of the date hereof, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
24 minutes ago
- Cision Canada
Moomoo's Parent Company Futu Releases Q2 2025 Results: Net Income up 105% YoY to US$339 Million
JERSEY CITY, N.J., Aug. 20, 2025 /CNW/ -- Moomoo's parent company Futu Holdings Ltd. ("Futu" or "the Company") (Nasdaq: FUTU), a leading global tech-driven online brokerage and wealth management platform, announced its unaudited Q2 2025 earnings with US$676.6 million in revenues, up 69.7% year-over-year ("YoY"), and US$338.8 million in non-GAAP adjusted net income, up 105.2% YoY. As of June 30, 2025, the Company reported 27.12 million registered users, 5.24 million brokerage accounts and 2.88 million funded accounts. The Company's total client assets surged to US$124 billion, demonstrating an accelerated growth of 17% quarter-over-quarter ("QoQ") and 68% YoY. Notably, the Hong Kong market reported strong net inflows, with average client assets increasing QoQ by double digits, while the Singapore market posted robust user growth, with one in every two Singapore residents now a moomoo user [1]. In Q2, the Company's total trading volume across its platforms grew by 12% QoQ and 121% YoY to US$457 billion, with US equities hitting US$343 billion, an all-time high. Singaporean, Australian, Japanese, and Canadian equities also recorded historical highs in quarterly trading volume. Cryptocurrency and AI Lead Product Innovation In the second quarter, cryptocurrency assets grew significantly by 43% QoQ across the Company's platforms. As the Company charts an ambitious course for the future of fintech, it has placed cryptocurrency expansion at the forefront of its business strategy. Following successful launches in Hong Kong and Singapore, the Company has introduced Moomoo Crypto to US investors. It is actively exploring and accelerating the rollout of cryptocurrency trading services across its global markets, aiming to build a one-stop investment platform that seamlessly connects virtual assets with traditional finance. At the same time, the Company is striving to build an end-to-end virtual asset infrastructure lifecycle. Leveraging multiple licenses obtained from regulators of various markets, the Company is set to provide a wide range of services including custody, matching and trading for virtual assets. The Company has launched cryptocurrency deposit and withdrawal services in Hong Kong, and has announced plans to explore offering around-the-clock on-chain tokenized money market fund trading services. In the future, the Company intends to offer more compliant crypto-related features to global investors. In addition to cryptocurrency, Artificial Intelligence ("AI") has been in the spotlight as more AI applications emerge in the fintech realm. In Q2, the Company introduced its self-developed blockbuster feature, Moomoo AI, an AI chatbot that empowers users worldwide to make smarter investment decisions with cutting-edge technologies. More advanced tech-driven functions are available in Moomoo Membership, which aims to provide exclusive premium benefits to members and provide value-added services. The Company continues to upgrade its platform features and enrich its product selections to meet various investor demands. In Japan, moomoo further expanded its capabilities in US stock assets by launching US stock options trading. In Malaysia, moomoo introduced IPO financing and earnings calendar features, enhancing the Malaysian stock trading experience. Meanwhile, the Company is improving trading features across various platforms, including launching the Options Strategy Builder feature on mobile and enabling funds and bonds trading on desktop. The recent Bullish IPO attracted strong interest on moomoo US platform, with 100% of moomoo subscribers successfully securing the shares. The moomoo app maintained the top position in Q2 downloads among local stock trading apps in Australia, Malaysia, Singapore, and Hong Kong [2]. Localization Strategy Drives Long-Term Market Growth In response to the rapid increase in demand for cryptocurrency and options related content from global users, moomoo introduced several dedicated educational sections within the in-app community. By the end of the second quarter, the community reported quarterly growth in daily active users, user generated content, and user engagement, with almost two million visits to the community's free educational online courses. In addition to online courses, moomoo also partnered with various organizations to promote financial literacy. In collaboration with Nasdaq and Japan Exchange Group, moomoo hosted its flagship offline event -- MooFest in Japan, attracting around 3,000 investors. Moomoo Malaysia joined forces with Bursa Malaysia to promote financial literacy, advancing the development of the local investment market. In the US, Moomoo Foundation and W!se, an educational nonprofit, presented awards to 100 high schools for their educational excellence in finance. Additionally, moomoo made a bold new presence at Citi Field, home of the American professional baseball team the New York Mets, with a 36-foot high moomoo signage, which significantly amplifies moomoo's brand visibility and recognition around the New York tri-state area. Moomoo also partnered with J.P. Morgan for the J.P. Morgan Corporate Challenge Singapore 2025 to promote wellness and an active lifestyle. Moomoo's dedicated localization efforts and product strengths garnered wide recognition across global markets, underscoring its growing influence in the fintech domain. In Malaysia, moomoo was honored by Bursa Malaysia with two prestigious awards - "Top Broker - Highest Number of New Accounts" and "Top Broker - Highest Traded Value". In Australia, moomoo secured the "2025 Canstar Outstanding Value" awards for traders, active investors, and casual investors, a testament to its broad appeal and "customer-first" business philosophy. In Singapore, moomoo clinched the "Fintech - Private Wealth Management" award at the SBR Technology Excellence Awards 2025. With all these accolades, moomoo reaffirms its commitment to enhancing customer value. The Company will continue to widen the products and features on the platform while maintaining its first-class services. About moomoo Moomoo is a leading global investment and trading platform dedicated to empowering investors with user-friendly tools, data, and insights. Our platform is designed to provide essential information and technology, enabling users to make well-informed investment decisions. With advanced charting tools, pro-level analytical features, moomoo evolves alongside our users, fostering a dynamic community where investors can share, learn, and grow together. Founded in the US, moomoo has expanded its global presence to serve investors across multiple markets, including Singapore, Australia, Japan, Canada, Malaysia, and New Zealand. As a subsidiary of a Nasdaq-listed company, moomoo is trusted by more than 27 million investors worldwide and has earned recognition from leading financial institutions and publications for its innovation and reliability.


Globe and Mail
33 minutes ago
- Globe and Mail
What's Wrong With Vertex Pharmaceuticals Stock?
Key Points Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline, which can lead to much more growth in the future. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process. This is the type of stock that you might expect to see taking off this year. But that isn't happening. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Instead, the share price of Vertex recently plunged. Excitement around the company has cooled drastically. What's wrong with Vertex Pharmaceuticals, and is it an investment worth buying on the dip, or could there be more trouble ahead for the healthcare stock? Vertex's stock tanks after underwhelming study On Aug. 4, Vertex released its latest quarterly numbers as well as results from a study for VX-993, which is a treatment for acute pain. It was the latter that had the most impact on the stock, and it wasn't good news. Vertex said that the treatment did not meet the primary endpoint in its phase 2 trial, and that it will not move on to further trials related to acute pain. The company has an approved pain medication, Journavx, which regulators approved earlier this year for moderate to severe acute pain. The non-opioid medication was a big win for the company, and investors were hoping VX-993 might be able to build on that success and potentially be a better option for patients. As is often the case with pharma stocks, bad news from a clinical trial can quickly send a stock into a tailspin. Before the recent news came out, Vertex's stock was trading at around $470. As of Tuesday, it had fallen to roughly $396. How the business looks today Despite the setback for Vertex, the business remains in solid shape. In its most recent quarter, which ended on June 30, the company's revenue rose by more than 12% year over year, to just under $3 billion. Vertex is on track to hit its guidance of around $12 billion in revenue for the full year, which would translate into an increase of 9% from the previous year. The company is a leader in cystic fibrosis drugs, and they account for nearly all of its revenue. But Vertex's business is broadening, and there is much more growth on the horizon. Journavx has only recently launched, and it brought in $12 million over the last three months. Casgevy, a gene therapy treatment for sickle cell disease and transfusion-dependent beta-thalassemia, has brought in over $30 million. Both of these products could be blockbusters, generating revenue of more than $1 billion at their respective peaks. What I like most about Vertex's business is its fantastic profit margins. Last quarter, the company's net income totaled $1 billion, which was 35% of its top line. With solid margins, the company can easily grow its profits in the long run, paving the way for a higher valuation. Vertex is a reasonably priced stock with a lot of potential upside According to analyst estimates, Vertex's stock is trading at 22 times its projected future earnings. That's modest given the average S&P 500 stock trades at a forward price-to-earnings multiple of 24. Vertex has the potential to be a tremendous growth stock to own in the long run. While the recent news around VX-993 may be disappointing, it shouldn't dissuade investors from investing in the business. Not every trial will turn out well, and not every drug will be a blockbuster. But with a growing portfolio of drugs and a highly profitable business, Vertex is one of the better healthcare stocks to buy and hold right now. Should you invest $1,000 in Vertex Pharmaceuticals right now? Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025


Toronto Star
6 hours ago
- Toronto Star
Blue Moon Metals Secures up to US$140 Million Project Finance Package from Hartree/Oaktree to Advance Flagship Nussir Project in Norway
TORONTO, Ontario, Aug. 19, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. ('Blue Moon' or the 'Company') (TSXV: MOON; OTCQX: BMOOF), is pleased to announce that it has entered into a memorandum of understanding with Hartree Partners, LP ('Hartree') and funds managed by Oaktree Capital Management, L.P. ('Oaktree', together with Hartree, the 'Lenders', and each a 'Lender') which consists of a previously agreed to bridge loan (the 'Bridge Loan') with Nussir ASA, a 93.55% owned subsidiary of the Company, as borrower, and Keystone Mines Inc., Blue Moon Norway AS and Repparfjord Eiendom AS, each a wholly owned subsidiary of the Company, as guarantors, as well as terms related a project financing package (the 'Project Finance Package' and together with the Bridge Loan, the 'Investment Package') which subject to various milestones, can provide for up to US$140 million of support for the continued development and construction of the Company's flagship, fully permitted Nussir Copper Project ('Nussir' or the 'Project'), located in Norway. The Project Finance Package terms include a US$50 million senior secured term loan (the 'Senior Secured Term Loan'), a US$70 million precious metals stream (the 'Redeemable Precious Metals Stream Agreement'), and an equity investment of up to US$20 million (subject to a 19.9% Oaktree / Hartree combined ownership limitation). The Project Finance Package is subject to customary approvals, diligence and closing conditions. The definitive Bridge Loan agreement has been signed. It is expected that the funds will be available for drawdown shortly thereafter, upon the finalization of customary post-closing security arrangements. Additionally, a subscription agreement for US$5 million has been signed and the corresponding equity issuance is expected to close on or about August 25, 2025. The Bridge Loan and equity investment will be subject to the approval of the TSX Venture Exchange (the 'TSXV').